Dr Oz nominated to lead CMS despite big pharma ties
Trump's nomination of Dr Oz has raised eyebrows, as a history of big pharma financial ties and questionable science hangs over him.
Corporate Governance
FDA shares additional draft guidance on CGTs
Trump 2.0 spells uncertainty for US healthcare, says analyst
Zentiva voices UWWTD concerns as EU grants approval
FDA approves Journey Medical’s rosacea treatment Emrosi
NCCN visits Vietnam in continued cancer care collaboration
Reeves’ 2024 budget promises life sciences investment
Global conflicts prompt GPEI to delay polio eradication target
